EP0984692A4 - Nouveaux inhibiteurs d'angiogenese - Google Patents

Nouveaux inhibiteurs d'angiogenese

Info

Publication number
EP0984692A4
EP0984692A4 EP98923719A EP98923719A EP0984692A4 EP 0984692 A4 EP0984692 A4 EP 0984692A4 EP 98923719 A EP98923719 A EP 98923719A EP 98923719 A EP98923719 A EP 98923719A EP 0984692 A4 EP0984692 A4 EP 0984692A4
Authority
EP
European Patent Office
Prior art keywords
angiogenesis inhibitors
novel angiogenesis
novel
inhibitors
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98923719A
Other languages
German (de)
English (en)
Other versions
EP0984692A1 (fr
Inventor
Mark T Bilodeau
Randall W Hungate
Richard L Kendall
Ruth Rutledge
Kenneth A Thomas Jr
Robert Rubino
Mark E Fraley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800681.0A external-priority patent/GB9800681D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0984692A1 publication Critical patent/EP0984692A1/fr
Publication of EP0984692A4 publication Critical patent/EP0984692A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
EP98923719A 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese Withdrawn EP0984692A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4807697P 1997-05-30 1997-05-30
US48076P 1997-05-30
GBGB9800681.0A GB9800681D0 (en) 1998-01-14 1998-01-14 Novel angiogenesis inhibitors
GB9800681 1998-01-14
PCT/US1998/010590 WO1998054093A1 (fr) 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese

Publications (2)

Publication Number Publication Date
EP0984692A1 EP0984692A1 (fr) 2000-03-15
EP0984692A4 true EP0984692A4 (fr) 2001-02-21

Family

ID=26312935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923719A Withdrawn EP0984692A4 (fr) 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese

Country Status (5)

Country Link
EP (1) EP0984692A4 (fr)
JP (1) JP2002501532A (fr)
AU (1) AU734009B2 (fr)
CA (1) CA2291709A1 (fr)
WO (1) WO1998054093A1 (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
EP1107958B1 (fr) 1998-08-29 2006-08-16 AstraZeneca AB Composes pyrimidiniques
CA2341409A1 (fr) * 1998-08-31 2000-03-09 Merck And Co., Inc. Nouveaux inhibiteurs d'angiogenese
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1188244B1 (fr) * 1999-03-26 2004-11-10 Microsoft Corporation Codage adaptatif sans perte de donnees alphabetiques finies
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
BR0113056A (pt) 2000-08-09 2003-07-08 Astrazeneca Ab Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
AU7652101A (en) 2000-08-09 2002-02-18 Astrazeneca Ab Cinnoline compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
CN1307173C (zh) 2000-12-21 2007-03-28 葛兰素集团有限公司 作为血管生成调节剂的嘧啶胺
KR100830082B1 (ko) 2001-01-05 2008-05-20 화이자 인크. 인슐린 유사 성장 인자 ι수용체에 대한 항체
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7279473B2 (en) 2001-12-17 2007-10-09 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
EP1490354A1 (fr) 2002-03-09 2004-12-29 Astrazeneca AB Derives de la pyrimidine substituee par 4-imidazolyle presentant une activite d'inhibition de cdk
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)
CN1747950A (zh) 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
EA010727B1 (ru) 2003-02-26 2008-10-30 Суджен, Инк. Аминогетероарильные соединения в качестве ингибиторов протеинкиназ
CA2516824A1 (fr) 2003-02-28 2004-09-10 Teijin Pharma Limited Derives de pyrazolo[1,5-a]pyrimidine
WO2004087707A1 (fr) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
JP2007515474A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
CA2578066C (fr) 2004-08-26 2011-10-11 Pfizer Inc. Composes d'aminoheteroaryle enantiomeriquement purs utilises comme inhibiteurs de proteine kinase
WO2006033795A2 (fr) * 2004-09-17 2006-03-30 Wyeth Methode d'utilisation de pyrazolo [1,5-a] pyrimidines substituees
DK1812440T3 (da) 2004-11-04 2011-01-31 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
EP1863848A4 (fr) 2005-03-31 2009-09-23 Agensys Inc Anticorps et molecules correspondantes qui se fixent aux proteines 161p2f10b
EP2444419A1 (fr) 2005-04-26 2012-04-25 Pfizer Inc. Anticorps de la P-Cadherine
JP5161777B2 (ja) 2005-09-07 2013-03-13 アムジェン フレモント インク． アクチビン受容体様キナーゼ−１に対するヒトモノクローナル抗体
WO2007035744A1 (fr) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
CN101277956A (zh) 2005-09-30 2008-10-01 阿斯利康(瑞典)有限公司 具有抗细胞增殖活性的咪唑并【1，2-a】吡啶
RU2008117298A (ru) 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Пиразолопиримидины как ингибиторы протеинкиназ
UA91129C2 (ru) 2006-05-09 2010-06-25 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
EP1900739A1 (fr) * 2006-08-30 2008-03-19 Cellzome Ag Dérivés de diazolodiazine comme inhibiteurs de kinases
US20100093760A1 (en) * 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
BRPI0718029A2 (pt) * 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2008078091A1 (fr) 2006-12-22 2008-07-03 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CA2693915A1 (fr) 2007-07-20 2009-01-29 Merck & Co., Inc. Derives de la pyrazolo[1,5-a]pyrimidine
WO2009033094A2 (fr) 2007-09-07 2009-03-12 Agensys, Inc. Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
EP2206714B1 (fr) * 2007-09-28 2015-01-21 Kyowa Hakko Kirin Co., Ltd. Agent destiné à la prévention et/ou au traitement de maladies cutanées
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009077334A1 (fr) * 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Dérivés innovants d'imidazo[1,2-a]pyridine et d'imidazo[1,2-b]pyridazine
WO2009085913A1 (fr) 2007-12-19 2009-07-09 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines utiles en tant qu'inhibiteurs de jak2
CA2718403A1 (fr) * 2008-03-13 2009-09-17 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2737597C (fr) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anticorps entierement humains diriges contre un antigene associe au melanome de masse moleculaire elevee et leurs utilisations
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
WO2010099363A1 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CA2766403A1 (fr) 2009-07-13 2011-01-20 Genentech, Inc. Procedes de diagnostic et compositions pour traitement d'un cancer
JP2013500991A (ja) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ，エルエルシー ｍＴＯＲ阻害剤および血管新生阻害剤併用療法
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
EP2475996A1 (fr) 2009-09-11 2012-07-18 F. Hoffmann-La Roche AG Procédé pour identifier un patient plus fortement susceptible de répondre à un anticancéreux
AU2010297344A1 (en) 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011073521A1 (fr) 2009-12-15 2011-06-23 Petri Salven Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
ES2607806T3 (es) 2010-02-12 2017-04-04 Pfizer Inc Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (fr) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
CN102791712B (zh) 2010-03-05 2015-07-01 协和发酵麒麟株式会社 吡唑并嘧啶衍生物
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
CA2802857C (fr) 2010-06-16 2018-09-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anticorps diriges contre l'endoplasmine et leur utilisation
EP2848940A1 (fr) 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Procédé pour identifier un patient avec une forte probabilité de réaction à une thérapie anticancéreuse
MX2013000676A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
WO2012012750A1 (fr) 2010-07-23 2012-01-26 Trustees Of Boston University Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée
EP2621928A1 (fr) 2010-09-27 2013-08-07 Proximagen Limited Composés 7-hydroxy-pyrazolo-[1,5-a]pyrimidine et leur utilisation comme antagonistes du récepteur ccr2
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
JP5802756B2 (ja) 2010-10-20 2015-11-04 ファイザー・インク スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
WO2012116040A1 (fr) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
EP2781216A4 (fr) 2011-09-02 2015-05-27 Kyowa Hakko Kirin Co Ltd Régulateur d'activité de récepteur de chimiokine
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
AU2011378675B2 (en) 2011-10-04 2017-10-05 Epsilogen Ltd IgE anti -HMW-MAA antibody
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
CN107629059B (zh) 2012-12-07 2020-07-28 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CA2905993C (fr) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Derives de 4-amino-pyrimidinyle-2-amino-phenyle substitues et compositions pharmaceutiques a base de ceux-ci en tant qu'inhibiteurs dejak2 et d'alk2
JP6542192B2 (ja) * 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
EP2970288A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
EP2970289A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Composés utiles en tant qu'inhibiteurs de la kinase atr
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015085132A1 (fr) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compose 2-amino -6-fluoro-n- [5-fluoro-pyridin -3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide utile comme inhibiteur de la kinase atr, sa préparation, différentes formes solides et dérivés radiomarqués de celui-ci
EP3126528B1 (fr) 2014-04-04 2021-08-18 Crown Bioscience, Inc. (Taicang) Méthodes permettant de déterminer la sensibilité à des inhibiteurs de mek/erk
WO2015155624A1 (fr) 2014-04-10 2015-10-15 Pfizer Inc. Dérivés de dihydropyrrolopyrimidine
NZ725496A (en) 2014-04-30 2019-11-29 Pfizer Cycloalkyl-linked diheterocycle derivatives
LT3152212T (lt) 2014-06-05 2020-05-11 Vertex Pharmaceuticals Inc. Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos
HUE044280T2 (hu) 2014-06-17 2019-10-28 Vertex Pharma Rosszindulatú daganatok kezelése Chk1- és ATR-gátlók kombinációjával
WO2016001789A1 (fr) 2014-06-30 2016-01-07 Pfizer Inc. Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
EP3177320B1 (fr) 2014-07-31 2021-01-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Anticorps monoclonaux humains dirigés contre l'epha4 et leur utilisation
WO2016097918A1 (fr) 2014-12-18 2016-06-23 Pfizer Inc. Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
EP3611506B1 (fr) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Prédiction de la réaction thérapeutique à alvocidib par profilage mitochondrial
WO2016178876A2 (fr) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
CA2985804A1 (fr) 2015-05-18 2016-11-24 Tolero Pharmaceuticals, Inc. Promedicaments de l'alvocidib a biodisponibilite augmentee
WO2017009751A1 (fr) 2015-07-15 2017-01-19 Pfizer Inc. Dérivés de pyrimidine
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
EP3355926A4 (fr) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
CA3047557A1 (fr) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Peptides de profilage et procedes de profilage de sensibilite
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019075367A1 (fr) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
AU2019391097A1 (en) 2018-12-04 2021-05-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR20210146290A (ko) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
US20220315581A1 (en) * 2019-06-14 2022-10-06 Medshine Discovery Inc. Fused ring compound as fgfr and vegfr dual inhibitor
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029109A1 (fr) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf
EP0795555A1 (fr) * 1995-09-28 1997-09-17 Otsuka Pharmaceutical Factory, Inc. Analgesiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795555A1 (fr) * 1995-09-28 1997-09-17 Otsuka Pharmaceutical Factory, Inc. Analgesiques
WO1997029109A1 (fr) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIRKPATRICK W E ET AL: "3-HALO-5,7-DIMETHYLPYRAZOLO U1,5-APYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL NERVOUS SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 20, no. 3, 1 March 1977 (1977-03-01), pages 386 - 393, XP000670076, ISSN: 0022-2623 *
See also references of WO9854093A1 *

Also Published As

Publication number Publication date
AU7594498A (en) 1998-12-30
WO1998054093A1 (fr) 1998-12-03
JP2002501532A (ja) 2002-01-15
CA2291709A1 (fr) 1998-12-03
AU734009B2 (en) 2001-05-31
EP0984692A1 (fr) 2000-03-15

Similar Documents

Publication Publication Date Title
EP0984692A4 (fr) Nouveaux inhibiteurs d'angiogenese
EP1017682A4 (fr) Nouveaux inhibiteurs de l'angiogenese
EP1109555A4 (fr) Nouveaux inhibiteurs d'angiogenese
EP1097147A4 (fr) Nouveaux inhibiteurs de l'angiogenese
ZA98376B (en) Sulfamide-metalloprotease inhibitors
DE69803272D1 (en) Hemmstoffe der stickstoffmonoxid-synthase
GB2321641B (en) Sulfamide-metalloprotease inhibitors
PL335999A1 (en) Substituted 3-cyanoquinolines
AP2000001795A0 (en) Substituted 4-aminothiazol-2-yol
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
PL316669A1 (en) Angiogenesis inhibitors
MX202707B (en) Scale inhibitors
HUP0202076A3 (en) Triazine angiogenesis inhibitors
IL135343A0 (en) Novel aryloxy-alkyl-dialkylamines
PL331803A1 (en) Bidonoric metaloprotease inhibitors
SI1036083T1 (en) Novel 9a-azalides
PL345574A1 (en) Angiogenesis inhibitors
IL130600A0 (en) Substituted 4-benzoyl-pyrazole
IL133261A0 (en) Substituted naphthropyrans
ZA985761B (en) Substituted aryluracils
GB9800681D0 (en) Novel angiogenesis inhibitors
GB9810544D0 (en) Novel angiogenesis inhibitors
GB9822700D0 (en) Novel angiogenesis inhibitors
AUPO820197A0 (en) Inorganic angiogenesis inhibitors
PL318601A1 (en) Novel 5-arylidene-4-oxo-2-imidazpglycines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991230

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010108

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 43/54 A, 7C 07D 487/04 B, 7A 61K 31/305 B, 7C 07D 487/04 J, 7C 07D 239:00 J, 7C 07D 231:00 J

17Q First examination report despatched

Effective date: 20021022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040224